Gautam Borthakur MD
Hematologic Oncology
Professor, Department of Leukemia, University of Texas Medical School at Houston
Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Borthakur is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2001 - 2004
Brooklyn Hospital CenterResidency, Internal Medicine, 1993 - 1996
Assam Medical CollegeClass of 1985
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 1996 - 2027
OK State Medical License 2020 - 2021
UT State Medical License 1996 - 1998
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
- Top Doctors:SE Texas Castle Connolly, 2013
Clinical Trials
- Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome Start of enrollment: 2009 Jan 01
- Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2007 Apr 04
- FTS Study in Patients With Advanced Hematologic Malignancies Start of enrollment: 2006 May 01
Publications & Presentations
PubMed
- Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.Roberta S Azevedo, Julie Braish, Georgina Gener-Ricos, Guilin Tang, Koji Sasaki
Leukemia & Lymphoma. 2026-01-01 - Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, Tapan M Kadia, Sanam Loghavi
Leukemia. 2025-12-10 - Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study.Celalettin Ustun, Mei-Jie Zhang, Andrew Peterson, Alexander Baek, Mounzer Agha
British Journal of Haematology. 2025-12-01
Journal Articles
- Response Kinetics and Factors Predicting Survival in Core-Binding Factor LeukemiaHagop Kantarjian, Gautam Borthakur, Tapan Kadia, Nature
Abstracts/Posters
- A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy...Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
- Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17pOctober 2017
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
Press Mentions
Cantargia Enrols First Patient in Trial of Nadunolimab for AML and MDSMarch 13th, 2025- Understanding the Types of LeukemiaAugust 3rd, 2022
Adhesion Molecules, Stem Cells, and the Microenvironment in Acute Myeloid LeukemiaMarch 3rd, 2016
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
